FDA approves new add-ons for the treatment of Parkinson's disease in adults

recently, the U.S. Food and Drug Administration approved the istradefylline tablet as an additional treatment for adult Parkinson's patients who experience a "closed" episode of the roving doba/carbidoba treatment. A "off" episode is when a patient's medication is ineffective, leading to an increase in Parkinson's symptoms, such as tremors and difficulty walking.
“ Parkinson's disease is a debilitating disease that severely affects a patient's life," said Eric Bastings, acting director of neurology products at the FDA's Center for Drug Evaluation and Research. Parkinson

is the second most common neurodegenerative disease in the United States after Alzheimer's disease, according to the National Institutes of Health. An estimated 50,000 Americans are diagnosed with Parkinson's disease each year, and about 1 million Americans suffer from the disease. Although neurological disorders can occur earlier, they usually occur in people over 60 years of age. This occurs when cells in the brain that produce dopamine chemicals are damaged or die. Dopamine helps send signals between brain regions, producing smooth, purposeful movements - such as eating, writing and shaving. The early symptoms of the disease are subtle and usually gradually worsen; However, the disease develops faster in some people than in others.In four 12-week placebo-controlled clinical studies, 1,143 participants showed the effectiveness of "off" seizures in pd patients who had been treated with zorianz/carbidoba. In all four studies, compared to patients treated with a placebo, the results showed that patients treated with Nourianz had significantly lower baselines during the daily "rest" period.We observed that the most common adverse reactions in patients taking Norianz included involuntary muscle movement (movement disorders), dizziness, constipation, nausea, hallucinations and insomnia (insomnia). We should monitor the development of motor disorders in patients or the deterioration of existing motor disorders. If hallucinations, psychotic behavior, or impulsive/compulsive behavior occur, consider reducing or stopping the dose of Norianz. Nourianz is not recommended during pregnancy. Contraceptives are recommended for fertile women during treatment.
FDA approves Kyowa Kirin, Inc.'s Norianz drug. （cyy123.com）